Transarterial chemoembolization versus radioembolization as a treatment option for single large (>5 cm) hepatocellular carcinoma: a retrospective study in South Korea

IF 4.9 3区环境科学与生态学 Q2 ENGINEERING, ENVIRONMENTAL

International Journal of Life Cycle Assessment Pub Date : 2023-08-25 DOI:10.54724/lc.2023.e13

Kwanjoo Lee, Jae Seung Lee, Do Young Kim

{"title":"Transarterial chemoembolization versus radioembolization as a treatment option for single large (>5 cm) hepatocellular carcinoma: a retrospective study in South Korea","authors":"Kwanjoo Lee, Jae Seung Lee, Do Young Kim","doi":"10.54724/lc.2023.e13","DOIUrl":null,"url":null,"abstract":"Objective: To date, there has been no study comparing transarterial chemoembolization (TACE) with transarterial radioembolization (TARE) in these patients, so this study was designed to determine which treatment is more effective and safer between TACE and TARE. Methods: From January 2011 to May 2017, patients who received TACE or TARE as a first-line treatment for single large hepatocellular carcinoma at Severance Hospital were reviewed retrospectively. We compared proportion of transition to curative surgery, response rate, the overall survival (OS), progression free survival (PFS). We also compared side effects, and post-procedure liver function between the two groups. Results: Baseline characteristics between the two groups showed no significant difference. There was no difference in the ratio who underwent radical resection and liver transplantation as follow-up treatment, and in OS and PFS. However, disease control rate at 3month was higher in TARE group (100.0% in TARE group versus 54.5% in TACE group, p = 0.009). And in terms of post-procedural side effects, fever was lower in the TARE group than TACE group (0.0% vs. 76.9%, p < 0.001), and length of hospital stay was shorter in the TARE group (3.79 vs. 5.92 days, p = 0.003). In the post-procedural lab, ALT was significantly lower in the TARE group on the day after the procedure. Conclusion: As a treatment for single large HCC under the same conditions, TARE is similar in terms of survival to TACE, but it is advantageous in terms of response rate and side effects. However, more follow-up studies are needed to increase reliability.","PeriodicalId":54952,"journal":{"name":"International Journal of Life Cycle Assessment","volume":null,"pages":null},"PeriodicalIF":4.9000,"publicationDate":"2023-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Life Cycle Assessment","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.54724/lc.2023.e13","RegionNum":3,"RegionCategory":"环境科学与生态学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENGINEERING, ENVIRONMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To date, there has been no study comparing transarterial chemoembolization (TACE) with transarterial radioembolization (TARE) in these patients, so this study was designed to determine which treatment is more effective and safer between TACE and TARE. Methods: From January 2011 to May 2017, patients who received TACE or TARE as a first-line treatment for single large hepatocellular carcinoma at Severance Hospital were reviewed retrospectively. We compared proportion of transition to curative surgery, response rate, the overall survival (OS), progression free survival (PFS). We also compared side effects, and post-procedure liver function between the two groups. Results: Baseline characteristics between the two groups showed no significant difference. There was no difference in the ratio who underwent radical resection and liver transplantation as follow-up treatment, and in OS and PFS. However, disease control rate at 3month was higher in TARE group (100.0% in TARE group versus 54.5% in TACE group, p = 0.009). And in terms of post-procedural side effects, fever was lower in the TARE group than TACE group (0.0% vs. 76.9%, p < 0.001), and length of hospital stay was shorter in the TARE group (3.79 vs. 5.92 days, p = 0.003). In the post-procedural lab, ALT was significantly lower in the TARE group on the day after the procedure. Conclusion: As a treatment for single large HCC under the same conditions, TARE is similar in terms of survival to TACE, but it is advantageous in terms of response rate and side effects. However, more follow-up studies are needed to increase reliability.

查看原文本刊更多论文

经动脉化疗栓塞与放射栓塞作为单个大(5厘米)肝细胞癌的治疗选择:韩国的一项回顾性研究

目的:目前尚无经动脉化疗栓塞(TACE)与经动脉放射栓塞(TARE)在这些患者中的比较研究，因此本研究旨在确定TACE与TARE哪种治疗更有效、更安全。方法:回顾性分析2011年1月至2017年5月在Severance医院接受TACE或TARE作为单发大肝癌一线治疗的患者。我们比较了过渡到根治性手术的比例、有效率、总生存期(OS)、无进展生存期(PFS)。我们还比较了两组的副作用和术后肝功能。结果:两组患者基线特征无显著差异。在接受根治性切除和肝移植作为随访治疗的比例、OS和PFS方面没有差异。TARE组疾病控制率高于TARE组(TARE组为100.0%，TACE组为54.5%，p = 0.009)。术后副作用方面，TARE组发热低于TACE组(0.0% vs. 76.9%， p <TARE组住院时间更短(3.79天比5.92天，p = 0.003)。术后实验室结果显示，术后1天TARE组ALT明显降低。结论:在相同条件下，TARE作为单发大肝癌的治疗方法，其生存期与TACE相似，但在有效率和副作用方面具有优势。然而，需要更多的后续研究来提高可靠性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Life Cycle Assessment 环境科学-工程：环境

CiteScore

10.60

自引率

10.40%

发文量

100

审稿时长

8-16 weeks

期刊介绍： The International Journal of Life Cycle Assessment (Int J Life Cycle Assess) is the first journal devoted entirely to Life Cycle Assessment and closely related methods. LCA has become a recognized instrument to assess the ecological burdens and impacts throughout the consecutive and interlinked stages of a product system, from raw material acquisition or generation from natural resources, through production and use to final disposal. The Int J Life Cycle Assess is a forum for scientists developing LCA and LCM (Life Cycle Management); LCA and LCM practitioners; managers concerned with environmental aspects of products; governmental environmental agencies responsible for product quality; scientific and industrial societies involved in LCA development, and ecological institutions and bodies.